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Abstract: Neural regeneration is of great interest due to its potential to treat traumatic brain injuries
and diseases that impact quality of life. Growth factor mediated differentiation can take up to
several weeks to months to produce the cell of interest whereas chemical stimulation may be as
minimal as a few hours. The smaller time scale is of great clinical relevance. Adipose derived stem
cells (ADSCs) were treated for up to 24 h with a novel differentiation media containing the cyclic
ketamine compounds to direct neurogenic induction. The extent of differentiation was investigated
by proteome changes occurring during the process. The treatments indicated the ADSCs responded
favorably to the neurogenic induction media by presenting a number of morphological cues of
neuronal phenotype previously seen and a higher cell population post induction compared to
previous studies. Furthermore, approximately 3500 proteins were analyzed and identified by mass
spectrometric iTRAQ analyses. The bioinformatics analyses revealed hundreds of proteins whose
expression level changes were statistically significant and biologically relevant to neurogenesis and
annotated as being involved in neurogenic development. Complementing this, the Bioplex cytokine
assay profiles present evidence of decreased panel of stress response cytokines and a relative increase
in those involved in neurogenesis.
Keywords: adult stem cells; adipose; neural; proteomics; cytokines; cyclic ketamine
1. Introduction
Stem cell sciences have advanced to the point where it is now possible to provide a range of tissues
and cell types to be used in transplantation for regenerative therapies for a wide variety of tissue and
organ types [1,2]. However, the production of neural cells from stem cells has been more difficult, and
therefore the application of stem cell technology to minimize impairments in neural function or the
discovery of compounds capable of the same has been more limited [3]. Prior studies of inducing stem
cells toward a neural phenotype most commonly utilized reducing agents or strong antioxidants such
as Beta-mercaptoethanol (BME), Dimethylsulfide (DMSO), and Butylated hydroxianisole (BHA) [4,5]
or similar compounds. In our previous work [6] these chemicals were implicated as having a strong
effect on reduction pathways and decreasing oxidative stress, thus acting as the instigating factor
driving the shift from stem cells toward a neural-like phenotype. Krabbe et al. [7], in a review have
questioned whether cytotoxic stress is the cause of the neuron-like morphology of MSCs undergoing
rapid change. This may well be the case with the above agents. However, if toxicity were the case
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for the morphological change, one would expect cell stress to show in both the metabolome and
proteome overtime.
The work presented here, biologically stable, and non-toxic chemicals with analogous effects on
mesenchymal stromal/stem cells (MSCs) to the above-mentioned chemicals have been examined
for their potential to drive MSCs towards a neural phenotypic differentiation. The cyclic
ketamine (CK) additives; lanthionine ketamine (LK), lanthionine ketamine ethyl ester (LKEE) and
S-aminoethyl-L-cysteine ketamine (AECK) established the optimal results producing cells that
resembled neural cells morphologically. The rationale behind testing these chemicals was that they have
a reductive capacity, however, they are non-toxic at the biologically relevant tested concentrations [8].
Briefly, CKs are cyclic sulfur-containing reducing agents that are naturally found in the brain and
CNS and have been reported with possessing pro-neural growth properties [8]. CKs basic chemical
structure resembles a modified version of the amino acid proline. The two R-groups allow for a wide
variety of synthetic and semi-synthetic side chain additions, for example branched-chain alkyl groups
and cycloalkyl (alicyclic) groups.
Previous studies with LK and LKEE have shown links to neurotrophic activity, promoting process
extension from neurons in vitro that have been shown to protect neurons against oxidative stress [9].
While lanthionine-related compounds have been used for the treatment of inflammatory disease [9]
and display antioxidant, neurotrophic, neuroprotective and neuritogenic activity [10], the capacity of
these molecules to cause formation of neural cells is unknown. The neurogenic effect on adult stem
cells has not been investigated.
This study investigates the proteomic changes of treating stem cells with CK molecules under
conditions permitting the formation of a cell having a neural morphological appearance consistent with
previous studies. The analysis of the proteome of the differentiated cells gives a deeper insight into the
molecular interactions of abundance-regulated proteins during treatment and, critically, whether the
cells are neural or simply neural-like with a significant stress response.
2. Results
2.1. Microscopy
The treatment of adipose derived stem cells (ADSCs) with the CK and CK derivatives was
conducted with the intention of producing cells that morphologically and phenotypically resemble
neural cells. A microscopy analysis allowed for the evaluation of the morphological changes produced
during the induction. All culture vessels were maintained at sub-confluency prior to addition
of differentiation media containing AECK, LK or LKEE. Figure 1A–H shows the rate of cellular
response over a 24 h period subsequent to the addition of the novel neurogenic differentiation media.
Figure 1B–D are AECK treated ADSCs at time points 3, 5, and 24 h respectively. The AECK treated
cells display minimal changes at 3 and 5 h with minor cytoskeletal shifts and retractions. The cells
appear to be marginally more slender than the basal cells whilst also producing a condensed nucleus.
The final time point exhibited marked changes with a majority of cells assuming a bipolar contouring
with a smaller population of approximately 20% showing evidence of process growth and neurite
extension similar to primary neural cells [11].
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Figure 1. (A) Basal human adipose derived stem cells (ADSCs) in vitro culture (non-induced). (B–D) 
human ADSCs induced with 0.5 μM AECK time points captured at 3, 5 and 24 h respectively. Time 
course shows minimal structural changes and some cellular contraction producing cells in (D) which 
are marginally more slender than those in (A). (E) Basal human ADSCs in vitro culture (non-induced). 
(F–H) human ADSCs induced with 0.6 μM lanthionine ketamine (LK) time points captured at 3, 5, 
and 24 h respectively. Time course adequately exhibits large structural reconfiguration of ADSCs 
during differentiation. Cells display bipolar elongation, process, and spindle formation. Microscopy 
images using a 10x objective lens; scale bar 100 μm. (I) The cell count for the time course of each 
treatment AECK (blue) and LK (red). 
The LK treatment produced visually significant morphological changes over time. At the 3-h 
time point, the cells are indistinguishable from the AECK treatment with minor cytoskeletal 
retractions toward the nuclei. Beyond the 5-h time point (Figure 1G) the strongest morphological 
changes from all trialed chemicals is visualized. The LK induced ADSCs are morphologically distinct 
and bear minimal to no resemblance to the parent basal ADSCs. Cells exhibit elongated membranes 
and are contracted, displaying a bipolar architecture with multipolar extensions reaching between 
cells producing visible junctures as seen in Figure 2C. The final time point shows the most expansive 
and uniform morphological differentiation within this study (Figure 1H). Nearly 95% of cells appear 
to share the multipolar and dendritic-like extension character in a near network formation. A notable 
complimentary result is the minimal cell death and low detachment numbers as observed in Figure 
2E. The harvested cells at the final time point presented a total dead/live ratio of 1:85; i.e., an average 
of 1.17% of cells stained blue with trypan, which is 10-fold less than the Beta-mercaptoethanol (BME) 
treated cells in Santos et al. [6]. 
Figure 1. Basal human adipos derived st m cells (ADSCs) in vitro culture (non-induced).
(B–D) human ADSCs induced with 0.5 µM AECK time points captured at 3, 5 and 24 h r spectively.
Time course shows inimal stru tural changes and some cellular contract on producing cells in
(D) which are marginally more slend r than those in (A). (E) Basal human ADSCs in vitro ulture
(non-induced). (F–H) human ADSCs induced with 0.6 µM la thionine ketamine (LK) time points
captured at 3, 5, and 24 h respectively. Time course adequately exhibits large structural reconfiguration
of ADSCs during differentiation. Cells display bipolar elongation, process, and spindle formation.
Microscopy images using a 10× objective lens; scale bar 100 µm. (I) The cell count for the time course
of each treatment AECK (blue) and LK (red).
The LK treatment produced visually significant morphological changes over time. At the 3-h time
point, the cells are indistinguishable from the AECK treatment with minor cytoskeletal retractions
toward the nuclei. Beyond the 5-h time point (Figure 1G) the strongest morphological changes from
all trialed chemicals is visualized. The LK induced ADSCs are morphologically distinct and bear
minimal to no resemblance to the parent basal ADSCs. Cells exhibit elongated membranes and
are contracted, displaying a bipolar architecture with multipolar extensions reaching between cells
producing visible junctures as seen in Figure 2C. The final time point shows the most expansive and
uniform morphological differentiation within this study (Figure 1H). Nearly 95% of cells appear to
share the multipolar and dendritic-like extension character in a near network formation. A notable
complimentary result is the minimal cell death and low detachment numbers as observed in Figure 2E.
The harvested cells at the final time point presented a total dead/live ratio of 1:85; i.e., an average of
1.17% of cells stained blue with trypan, which is 10-fold less than the Beta-mercaptoethanol (BME)
treated cells in Santos et al. [6].
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Figure 2. Volcano plots (A–C) showing p-values versus protein fold change (log2) of ADSCs and 
comparisons generated with DanteR. Quantitation criteria cutoff of statistically significant p-values < 
0.05 and fold change log2 ratio cutoff of <−0.2 or >0.2. The blue nodes represent the above >0 log fold 
change, i.e., up-regulated proteins and the below <0 fold change down-regulated proteins. The grey 
nodes represent the not significantly changed proteins with a p-value > 0.05 and within the cut off for 
fold change. (D,E) Three-way Venn diagrams of up and down regulated proteins. Diagrams include 
the AECK treated, LK treated hADSCs, and the GBCs showing unique and shared proteins. (D) up 
regulated proteins revealing there are 31, 76, 384 with 91, 10, 18 shared proteins between each of the 
corresponding tested cell lines as well as 5 shared proteins between all three relative to basal hADSCs. 
(E) down regulated proteins revealing there are 51, 31, and 368 unique proteins with 43, 8, and 48 
shared proteins between each of the corresponding tested cell lines as well as 36 shared proteins 
between all three relative to basal hADSCs. 
2.2. iTRAQ Proteome Comparisons of Chemically Induced hADSCs Toward Neural Lineage 
The digested proteins from each cell line were labelled with the iTRAQ isobaric tags as follows: 
hADSCs, AECK differentiated hADSCs, LK differentiated hADSCs, and Glioblastoma cells (GBC) 
were labelled with 114, 115, 116 and 117 isobaric tags respectively. The protein fold changes between 
samples were done comparatively and are relative to a base denominator, which was the basal 
hADSCs114, i.e., 115 vs. 114, 116 vs. 114 and 117 vs. 114. This was executed to elucidate the relative 
protein fold changes across the detected and quantifiable proteome of the differentiating cells, 
determining the changes in the abundance of protein species over time during differentiation. 
Table 1 summarizes the results of the iTRAQ experiment. The summary table shows the upper 
99%, 95%, and 66% cut off for significant protein ratio change detected by the iTRAQ quantification. 
The upper 95% range was chosen for all data analysis and, within that cutoff, the complete analysis 
had a total of 2430 proteins, consisting of 36,993 distinct peptides identified from 178,574 spectra 
(protein, peptide, and spectra FDR analysis supplementary material). An average of 6.38 peptides 
was matched per protein with an average of 18% sequence coverage from the total cohort of the 
detected proteins (Supplementary Table S1). Proteins were removed from the analysis if they were 
identified by less than 5 quantifiable peptides/protein to increase the robustness of the dataset and 
Figure 2. Volcano plots (A–C) showing p-values versus protein fold change (log2) of ADSCs and
comparisons generated with DanteR. Quantitation criteria cutoff of statistically significant p-values
< 0.05 and fold change log2 ratio cutoff of <−0.2 or >0.2. The blue nodes represent the above >0
log fold change, i.e., up-regulated proteins and the below <0 fold change down-regulated proteins.
The grey nodes represent the not significantly changed proteins with a p-value > 0.05 and within the
cut off for fold change. (D,E) Three-way Venn diagrams of up and down regulated proteins. Diagrams
include the AECK treated, LK treated hADSCs, and the GBCs showing unique and shared proteins.
(D) up regulated proteins revealing there are 31, 76, 384 with 91, 10, 18 shared proteins between each
of the corresponding tested cell lines as well as 5 shared proteins between all three relative to basal
hADSCs. (E) down regulated proteins revealing there are 51, 31, and 368 unique proteins with 43, 8,
and 48 shared proteins between each of the corresponding tested cell lines as well as 36 shared proteins
between all three relative to basal hADSCs.
2.2. iTRAQ Proteome Comparisons of Chemically Induced hADSCs toward Neural Lineage
The digested proteins from each cell line were labelled with the iTRAQ isobaric tags as follows:
hADSCs, AECK ifferentiated hADSCs, LK differ ntiated hADSCs, and Glioblastoma cells (GBC) were
labelled with 114, 115, 116 and 117 isobaric tags respectively. T e protein fold changes between samples
r done comparatively and are relative to a base denominator, which was the bas l hADSCs114,
i.e., 115 vs. 114, 116 vs. 114 and 117 vs. 114. This was executed to elucidate the relative protein fold
changes across the detected and quantifi ble proteome of the differentiating c lls, et rmining th
changes in the abundance of protein species over time during differentiation.
Table 1 summariz s the r sults of the iTRAQ xperim nt. The summary table shows the upper
99%, 95%, and 66% cut off for significant protein ratio change detected by the iTRAQ quantification.
The upper 95% range was chosen for ll data analysis and, within that cutoff, the complete an lysis
had a total of 2430 proteins, consisting of 36,993 distinct peptides identified from 178,574 spectra
(protein, peptide, and spectra FDR analysis suppleme tary material). An average of 6.38 pe tides
was matched per protein with an average of 18% sequence cover ge from the total cohort of the
detected proteins (Supplementary Table S1). Proteins were removed from the analysis if they were
i entified by less than 5 quantifiable peptides/protein to increase the r bustness of the dataset and
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the conclusions drawn. The subsequent cut offs utilized were based on p-value (<0.05) and fold
change (log2(ratio) less than −0.2 or greater than 0.2). These criteria refine the analysis to statistically
significant proteins that have an average of 20 matched peptides per protein, increasing confidence
in the data. The ProteinPilot group file, the protein summaries and peptide summary (without
background corrections) were exported to XML format for further analysis with specified denominators
for inter-sample comparisons through the generation of box and whisker plots, volcano plots and gene
ontology graphs in DanteR [12].
Table 1. Number of proteins and peptides identified by ProteinPilot after iTRAQ LC/MS/MS
analysis of human adipose derived stem cells (hADSCs), S-aminoethyl-L-cysteine ketamine (AECK)
differentiated, LK differentiated and Glioblastoma cells. Confidence cutoffs are the proteins with










>2.0 (99) 2108 2774 35,891 176,734 67.3
>1.3 (95) 2430 3204 36,993 178,574 68.0
>0.47 (66) 2741 5246 38,381 180,467 68.8
Cutoff applied: >0.05 (10%) 3491 15,271 41,011 184,078 70.1
Figure 2A–C are the comparative volcano plot layouts of the protein identifications of each iTRAQ
labelled ADSC treatment with either AECK or LK and finally the GBC relative to ADSCs. The graphs
show the expression differences by fold change (x-axis) and statistical significance by p-value (y-axis)
of all captured and identified proteins compared to the basal ADSCs. The blue nodes represent the
above >0.2 log fold change up-regulated proteins and the below <0.2 fold change down-regulated
proteins. The grey nodes represent the not significantly changed proteins with a p-value > 0.05 and
within the cut off for fold change. The representation of this data in this format is relevant to assess the
range and extent of fold changes and statistical significance occurring across the entire global analysis
in a single figure as well as trend comparisons between figures. This also allows for the selection of
the most changed proteins in each plot and simultaneous comparison and position selection of the
same protein in neighboring plots, thus streamlining comparisons for large iTRAQ datasets. From the
volcano plots (Figure 2A–C), Venn diagrams were constructed (Figure 2D,E) representing the number
of proteins unique and shared between both replicates for each chemical treatment of the ADSCs.
(All the statistically significant proteins are available in Supplementary Table S2.)
2.3. Interaction Network Analysis of CK Treated ADSC Proteomes
The open source software Cytoscape [13] works in conjunction with several large annotated
databases of protein–protein and protein–DNA interactions that are increasingly available for a variety
of organisms. Databases such as Gene Ontology, SwissProt, Ensembl, TrEMBL, UniProt, PDB, EBI,
RCSB and STRING are well curated and are easily integrated into the search algorithms. Proteins within
the interaction network are represented as nodes and the interactions linking nodes are lines known as
edges. The spectrum of edges displayed in networks vary slightly in depth between software; the most
common are binding, reaction, catalysis, activation, inhibition, phenotype similarity, post-translational
modification, and expression, all of which are sample dependent. Figure 3A is a Cytoscape constructed
interaction network from the iTRAQ results representative of the 95% confidence cut off, presenting
2430 unique proteins nodes each individually colored with a cumulative 90,855 annotated or canonical
interactions between proteins across the network presented in grey edge lines. To reduce complexity
and focus analysis on the ”up” or ”down” regulated proteins, Figure 3B presents the full network with
all statistically significant and fold-change criterion cut-off of up-regulated protein nodes present in
blue and down-regulated protein nodes in red. Figure 3C displays only the up and down regulation as
blue and red respectively, in addition to presenting the protein nodes unique to AECK and LK as well
as those that are shared as different symbols. AECK protein nodes are “triangles”, LK protein nodes are
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“squares” and shared protein nodes are “circles”. Thus displaying, collectively 448 protein nodes with
5425 interaction edges across this subsidiary network. Figure 3D,E presents the relevant up and down
regulated proteins from the aforementioned interaction network in Figure 3C as the correlative gene
ontology terms. Figure 3D specifies the up regulation of proteins involved in neural differentiation
of which a large proportion is involved in neurogenesis and axonogenesis. Complementary to this is
Figure 3E which presents the down regulated proteins involved in stress, apoptosis, glial differentiation,
and regulation of signaling pathways. Refining this information to particular proteins and their relative
biological and statistical significance by abundance and fold changes is presented in Tables 2–5.
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Figure 3. Interaction Networks (A) Presents the iTRAQ dataset of 2430 unique proteins nodes each
individually colored with a cumulative 90,855 annotated or canonical interactions between proteins
across the network presented in grey edge lines. (B) Presents the iTRAQ dataset of the full network with
all up-regulated protein nodes present in blue and down-regulated protein nodes in red. (C) Presents
the AECK unique protein nodes as “triangles”, LK protein nodes as squares and shared protein nodes
as “circles”. This is in conjunction with the color indication of up regulated proteins in blue and down
regulated in red. (D,E) number of up and down regulated proteins by GO terms respectively.
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Table 2. Summary of biologically and statistically significant up-regulated neural-related proteins identified in iTRAQ of hADSCs treated with AECK.
AECK Neural Accession Name GO Biological Process Peptides (95%) Fold Change p-Value
O75369 Filamin-B GO:0030154 cell differentiation 129 1.230453968 2.44 × 10−15
P00367 Glutamate dehydrogenase 1, mitochondrial GO:0006537 glutamate biosynthetic process 12 1.339429975 0.01273619
P09429 High mobility group protein B1 GO:0031175 neuron projection development 16 1.15634203 0.03726548
P10599 Thioredoxin GO:0008283 cell proliferation 7 1.57030201 0.04286075
P15144 Aminopeptidase N GO:0030154 cell differentiation 32 1.223500967 1.10 × 10−5
P15559 NAD(P)H dehydrogenase (quinone) 1 GO:0007271 synaptic transmission, cholinergic 9 1.816967964 0.002394901
Q00610 Clathrin heavy chain 1 GO:0048011 nerve growth factor receptor
signalling pathway
69 1.205008984 7.17 × 10−7
Q01082 Spectrin beta chain, brain 1 GO:0007411 axon guidance 54 1.284289956 3.63 × 10−10
Q06830 Peroxiredoxin-1 GO:0008283 cell proliferation 25 1.434638977 0.008896183
Q09666 Transforming protein RhoA GO:0007399 nervous system development 16 1.167513967 0.019935589
Q09666 Neuroblast differentiation-associated protein AHNAK GO:0007399 nervous system development 285 1.527696013 1.40 × 10−45
Q13813 Spectrin alpha chain, brain GO:0007411 axon guidance 71 1.29076004 6.27 × 10−14
P63000 Ras-related C3 botulinum toxin substrate 1 GO:0048011 nerve growth factor receptor
signaling pathway
7 1.664183 0.006588
Q9P0L0 Vesicle-associated membrane protein-associated protein A GO:0031175 neuron projection development 10 1.441416979 0.006864889
Table 3. Summary of biologically and statistically significant up-regulated neural-related proteins identified in iTRAQ of hADSCs treated with LK.
LK Neural Accession Name GO Biological Process Peptides (95%) Fold Change p-Value
O75369 Filamin-B GO:0030154 cell differentiation 129 1.372761965 0.0149013
P06396 Gelsolin GO:0060271 cilium morphogenesis 23 1.32772994 0.001008915
P10599 Thioredoxin GO:0008283 cell proliferation 4 1.76563704 0.02659229
P11142 Heat shock cognate 71 kDa protein GO:0007269 neurotransmitter secretion 73 1.381860971 0.00224432
P11413 Glucose-6-phosphate 1-dehydrogenase GO:0001816 cytokine production 23 1.242061019 0.00224432
P15144 Aminopeptidase N GO:0030154 cell differentiation 32 1.44699502 0.019935589
P17931 Galectin-3 GO:0030154 cell differentiation 7 1.757151961 0.006587825
Q01082 Spectrin beta chain, brain 1 GO:0007411 axon guidance 54 1.506716013 6.27 × 10−14
Q09666 Neuroblast differentiation-associated protein AHNAK GO:0007399 nervous system development 285 1.659075022 2.00 × 10−25
Q13813 Spectrin alpha chain, brain GO:0007411 axon guidance 71 1.395959973 6.27 × 10−14
Q92974 Rho guanine nucleotide exchange factor 2 GO:0048011 nerve growth factor receptor
signaling pathway
9 1.163854957 0.033079
P63000 Ras-related C3 botulinum toxin substrate 1 GO:0048011 nerve growth factor receptor
signaling pathway
7 1.616315960 0.006153737
Q9P0L0 Vesicle-associated membrane protein-associated protein A GO:0031175 neuron projection development 10 1.531931043 0.039667
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Table 4. Summary of significant up-regulated stress-related proteins identified in iTRAQ of hADSCs treated with AECK.
AECK Stress Accession Name GO Biological Process Peptides (95%) Fold Change p-Value
P01892 HLA class I histocompatibility antigen, A-2
alpha chain
GO:0060333 interferon-gamma-mediated signaling pathway 4 1.4692 0.01600371
P04083 Annexin A1 GO:0006954 inflammatory response 45 1.3066 0.00108737
P04264 Keratin, type II cytoskeletal 1 GO:0006979 response to oxidative stress 13 2.0287 0.00100892
P06396 Gelsolin GO:0006921 cellular component disassembly involved in apoptosis 25 1.3732 2.05 × 10−13
P09429 High mobility group protein B1 GO:0002437 inflammatory response to antigenic stimulus positive
regulation of apoptosis
16 1.1563 0.00754318
P11413 Glucose-6-phosphate 1-dehydrogenase GO:0034599 cellular response to oxidative stress 23 1.2994 0.00129321
P15121 Aldose reductase GO:0006950 response to stress 9 1.3973 0.00414161
P16070 CD44 antigen GO:0060333 interferon-gamma-mediated signaling pathway 15 1.3484 8.89 × 10−5
P30044 Peroxiredoxin-5, mitochondrial GO:0034614 cellular response to reactive oxygen species
inflammatory response
9 1.3299 0.00063648
P35611 Alpha-adducin GO:0006921 cellular component disassembly involved in apoptosis 12 1.5308 4.06 × 10−12
P51572 B-cell receptor-associated protein 31 GO:0006921 cellular component disassembly involved in apoptosis 7 1.4834 0.00252419
P61586 Transforming protein RhoA GO:0050772 positive regulation of axonogenesis 16 1.1675 0.00013793
P63000 Ras-related C3 botulinum toxin substrate 1 GO:0008624 induction of apoptosis by extracellular signals 7 1.6642 3.48 × 10−6
P63000 Ras-related C3 botulinum toxin substrate 1 GO:0006954 inflammatory response 7 1.6642 0.00016355
P63241 Eukaryotic translation initiation factor 5A-1 GO:0006917 induction of apoptosis 20 1.4873 6.36 × 10−12
Q02952 A-kinase anchor protein 12 GO:0030819 positive regulation of cAMP biosynthetic process 17 1.3261 0.0067851
Q03135 Caveolin-1 GO:0009267 cellular response to starvation; inactivation of MAPK
activity; positive regulation of calcium ion transport
into cytosol; positive regulation of canonical Wnt
receptor signaling pathway; response to hypoxia
7 3.1097 0.02121297
Q13813 Spectrin alpha chain GO:0006921 cellular component disassembly involved in apoptosis 71 1.2908 0.00131438
Q15149 Plectin GO:0006921 cellular component disassembly involved in apoptosis 174 1.3019 2.20 × 10−9
Q9NR28 Diablo homolog, mitochondrial GO:0008625 induction of apoptosis via death domain receptors 6 1.2655 2.20 × 10−9
Table 5. Summary of significant up-regulated stress-related proteins identified in iTRAQ of hADSCs treated with LK.
LK Stress Accession Name GO Biological Process Peptides (95%) Fold Change p-Value
P02545 Prelamin-A/C GO:0006921 cellular component disassembly involved in apoptosis 63 1.4487 3.04 × 10−9
P06396 Gelsolin GO:0006921 cellular component disassembly involved in apoptosis 23 1.3277 0.00031779
P08670 Vimentin GO:0006921 cellular component disassembly involved in apoptosis 199 1.2634 7.44 × 10−5
P11413 Glucose-6-phosphate 1-dehydrogenase GO:0034599 cellular response to oxidative stress 23 1.2421 0.00100042
P35611 Alpha-adducin GO:0006921 cellular component disassembly involved in apoptosis 12 1.5308 0.02401391
P36776 Lon protease homolog, mitochondrial GO:0034599 cellular response to oxidative stress 17 1.4223 0.0050889
P51572 B-cell receptor-associated protein 31 GO:0006921 cellular component disassembly involved in apoptosis 7 1.5205 0.00379271
Q03135 Caveolin-1 GO:0009267 cellular response to starvation; inactivation of MAPK activity 7 2.5188 0.00436605
Q13813 Spectrin alpha chain, brain GO:0006921 cellular component disassembly involved in apoptosis 71 1.396 9.24 × 10−15
Q15149 Plectin GO:0006921 cellular component disassembly involved in apoptosis 174 1.569 2.06 × 10−39
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2.4. Cytokine Levels
The Bioplex assay is a multiplex system for investigating the relative quantitative changes of up
to 27 cytokines across multiple sample types simultaneously. Section 3.2 covers in detail the relevance
of cytokines to neurogenic differentiation. Aliquots of the differentiation media supplemented with
either AECK or LK were collected at time points 0, 1, 3, 5, 20 and 24 h and the 27 cytokines measured.
An amount per cell (pg/cell) normalization was completed (Supplementary Table S3A,B) to adjust
for any discrepancies due to cell death which was apparent in previous studies and, to a limited
extent, in the LK and AECK samples. A single tail dendogram heatmap was generated using Euclidean
hierarchical clustering for cytokines trends over the differentiation time points (Figure 4A,B). Cytokines
have a variety of functions in cellular processes and are often expressed in response to a change
in a system which in turn can also regulate the expression of other molecules [14]. Individually
and collectively their relative concentrations can be related to particular cellular events or response
mechanisms. With this in mind, a number of trends can be observed within the Bioplex temporal ADSC
differentiation data set. The comparison of the Bioplex results between AECK and LK treated ADSCs
present similar trends with variations within the clustered groups as marked with the hierarchical
dendogram. AECK and LK treated ADSCs present 7 notable clustered groups in Figure 4A,B.
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3. Discussion
The premise of utilizing CK compounds in an attempt to induce ADSCs toward a neural linage
was based on several factors pertaining to their chemical properties as well as previous biological
observations. Firstly, based on the chemical properties, ketamines are a natural class of sulfur and
nitrogen-containing cyclic compounds with reductive activity [15] which are key features of the
previously studied simple chemical neurogenic inducing agents, BME and DMSO [6,16]. Furthermore,
CK is primarily found in the brain as a natural metabolic by product of the transamination of
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sulfur-containing amino acids [17,18]. LK and AECK have been purified from bovine brain and
binding and interaction studies have been successfully completed in the presence other brain specific
imine reductases [19]. LK has also been observed to exhibit neuroprotective, neurotrophic and
anti-inflammatory activities [10]. Additionally, the derivative LKEE displayed a higher efficiency for
membrane permeability and was revealed to protect motor neurons from oxidative stress in vitro
as well as promote neurite outgrowth at nanomolar concentrations [10,20]. The AECK molecule
has been noted to react with a similar chemistry to LK and LKEE and is thought to play similar
physiological and biochemical roles [21]. The group has also been shown to prevent ischemic neuronal
injury via the innate neuroprotective function [22]. CKs are now noted as novel neurotrophic small
molecules that hold some promise for the treatment of neurodegenerative diseases [23]. The use
of these stable, non-toxic and naturally occurring chemical for promoting the differentiation of a
heterogeneous mesenchymal stromal/stem cell population toward a neurogenic lineage was tested
and the phenotypic characterization by proteomic quantification was completed.
3.1. Neurogenic Related Roles of Identified Proteins
It is now recognized that protein interactions are not random events, their interfaces being
precisely coordinated spatially and temporally according to biological and environmental cues [24].
In stem cell biology, these signals affect protein-protein interactions, which regulate the molecular
processes of proliferation and differentiation. The systems biology approach of visualizing interacting
proteins within a proteome presents in silico datasets as graphical a network representation at a global
proteome scale and has become a significant tool in understanding the biological context in which
proteins function and localize to promote complex cellular events.
The action of CKs have been previously shown to have an effect through primary interactions
with thiomorpholine-carboxylate dehydrogenase and µ-crystallin proteins [9,10]. These initiating
factors are likely responsible for potentiating the downstream crosstalk interaction between the
MAP3K and Wnt/β-catenin pathways [25], which are vital in neural development. Complementary to
pathway promotions, numerous correlative interacting protein targets and partners have statistical up
regulation of and biologically relevant fold changes that support neurogenic differentiation, neurite
migration as well as neuron and axon development. Furthermore, the reductive capacity of the
chemicals also regulates oxidative stress and anti-inflammatory conditions. Whereby a substantial
number of cellular damaging stress related proteins and cytokines, previously observed in BME
treatment in Santos et al. [6], have been minimized in their expression. Therefore, consolidating the
CKs gentle inductive capacity for neural differentiation. The investigation of the roles and interacting
partners of up-regulated neural related proteins is important to comprehend the biological context of
their expression.
Filamin-B was identified in both chemically treated ADSCs with a statistically significant up
regulation in each differentiated cell. Filamin-B is an actin-binding protein that is highly expressed in
the CNS, displaying roles in cellular migration and differentiation [26]. The relevance of Filamin-B
in neurogenic differentiating ADSCs stems from its annotated role in neuroblast migration in the
developing brain from the ventricular zone to the outer cortical plate [26]. The migratory roles are
linked to the interaction between Filamin-B and its 70% homologous interacting partner Filamin-A,
which promotes the development and maintenance of the cell’s bipolar shape [27]. The up regulation
of Filamin-B in treated ADSCs is significant since the morphological shape of the treated cells appear
elongated and bipolar prior to the development of neurite outgrowth (Figure 1G,H). An interesting
binding partner was also identified within the statistically relevant proteins of both treatments.
The partner; Ras-related C3 botulinum toxin substrate 1 (Rac1) is annotated with the biological
process of nerve growth factor receptor signaling pathway and is a neural surface antigen. Rac1 is a
pleiotropic regulator of a variety of cellular processes including the proliferation, differentiation, and
neuronal maturation during embryonic and adult hippocampal development [28]. The assistance in
axonal migration and dendritic development is directed via its signaling with a dense core of primary
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interacting proteins of the P21 protein (Cdc42/Rac) activated kinase family. This acts as a GTPase
effector that links the action to the JNK/MAPK pathway regulating the spatial reorganization of the
cytoskeleton for neural development and dendrite morphogenesis [29]. The identification of Rac1
in neuronal differentiating ADSCs indicates the morphological changes observed are maintained
and directed through a number of control mechanisms that are widely seen in the development of
in vivo neural tissue. Rac1 has the potential to be utilized as a novel marker for neurogenesis of
ADSCs. The identification of Rac1 in neural differentiating ADSCs has the potential to be utilized as a
novel marker for neurogenesis. This finding further supports the CK induction of ADSCs toward a
neural phenotype.
Thioredoxin and Peroxiredoxin-1 were abundantly expressed in both chemical treated ADSCs.
Each protein is found ubiquitously in mammalian cells [30] thus they would not be suitable as a
neurospecific marker. Their function however is of great importance especially within the context
of this study’s focus on chemical induction and role of low oxidative stress. All Peroxiredoxins
contain a conserved cysteine residue which undergoes a cycle of peroxide-dependent oxidation and
thiol-dependent reduction [31]. This is particularly relevant since it regulates the intracellular redox
state, effectively protecting the cells from oxidative stress. This may occur, to a certain extent, based on
the oxidative-stress response proteins seen up regulated with BME treatment in a previous paper [6].
A study by Simzar et al. [32] found that the overexpression of peroxiredoxin in PC12 neuronal cells
in vitro increased the presence of reactive oxygen species, essentially creating an oxidative stress
inducing environment, this does not seem to be the case in this study as the cell population is
maintained at sufficiently high numbers. The activity of Peroxiredoxin-1 is regulated by thioredoxin,
which reduces the cysteine in peroxiredoxin [33]. The regulatory mechanisms maintaining the levels of
peroxiredoxin and thioredoxin levels are essential in preserving cells in distress. A system of controlled
oxidative stress has been shown to increase neurogenesis and oligodendrogenesis in adult neural
progenitor cells [34]. The importance of expression and regulation of these two molecules in sustaining
cells for proliferation and guiding neurogenesis is essential; furthermore, it can be used as a marker of
the level of stress experienced by neurogenic induced cells.
The network dynamics across both AECK and LK treated cells presented a range of
shared and highly interactive neuronal-related proteins, and the identification of Neuroblast
differentiation-associated protein (AHNAK) as a hub for many interactions supports the conclusion
that a differentiation process is occurring. Furthermore, AHNAK binding partners annexin2 and
S100-A10 were also identified with at least a two-fold increase over basal levels. The established
GO classification for AHNAK is its involvement in nervous system development. It has also been
recognized to have multiple roles in neuronal development dependent on its cellular localization and
calcium concentrations which regulates actin cytoskeleton organization, cell membrane architecture
and cell-cell junction formation [35–39]. Moreover, the non-membrane bound AHNAK promiscuously
interacts with several reported partners such as protein kinase C and phospholipase C which are
involved in the activation of inositol metabolism [40–42]. Protein kinase C and phospholipase C were
both found to be statistically significantly up regulated in both the AECK and LK treated ADSCs.
Inositol metabolism is vital in regulating the Wnt/β-catenin pathway for nerve guidance, serotonin
modulation and the control of intracellular calcium concentration [40,42]. There is mounting evidence
for the usefulness of AHNAK as a marker for neurogenesis especially in the co-expression and up
regulation of neuronal development related binding partners. This is further evidence that the CKs are
more suitable for inducing neurogenesis of ADSCs.
An associated multifunctional-actin binding protein uniquely identified in the LK treated ADSCs
is Gelsolin. Gelsolin localization and expression has been determined to be highest in the CNS and PNS
and it has been found to be involved in a number of growth promoting and neuroprotective functions
mediated possibly through the Wnt/β-catenin pathway [43]. Its role in actin remodeling in the
nervous system is calcium dependent, with the protein initiating actin polymerization or disassembly.
Since the highest expression has been determined to be in the oligodendrocytes and Schwann cells
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myelin sheaths, Tanaka et al. [43] proposed the role of gelsolin to be involved in the maturation of
the myelin sheath forming cells. The neuroprotective capability is attributed to its anti-oxidative and
anti-apoptotic functions in high oxidative-stress induced environments [44]. Interestingly the down
regulation or proteolytic cleavage of gelsolin has been linked to the development of Alzheimer’s
disease [45]. The up regulation of Gelsolin in the CK treated ADSCs and its value as a neuronal
marker is apparent, since the presence of a neuronally related cytoskeletal remodelling protein with
neuroprotective capabilities is an appealing find in the array of up regulated proteins of neurogenic
differentiating ADSCs. This is further evidence that the CK chemicals are better suited for inducing
neurogenesis in ADSCs.
Spectrin alpha and beta chain has been widely studied and are known to be major cytoskeletal
components in the brain and distributed in the cytoplasm of neural cells and is modularly downstream
regulated by the Wnt signaling pathway [46]. There is now evidence that spectrin regulates the surface
chemistry and morphology of neuronal cells and large modifications or degradation would produce
major modifications to synapses [46]. Spectrin has also been implicated in the calcium regulated release
of neurotransmitters between developing synapses [47]. The regulation of spectrin is derived from the
calcium modulated calpain proteolytic enzyme [46]. The levels of calpain in both chemical treatments
in this study are negligible. Here the presence of a heterodimer of the brain isoforms of spectrin alpha
and beta chain is well noted in the prospect of utility as a neural marker for further studies.
Lastly Galectin-3 increase in expression has been detected in the LK treated ADSCs. Recent studies
have shown that galectin-3 is expressed in a variety of neuronal tissues, especially glial cells in the CNS
in which it directs oligodendrocyte differentiation to control myelin sheath formation [48]. Furthermore,
the control of neuroblast migration in brain development was proposed by Comte et al. [49]. A function
that is more suited to the development of neuronal like cells was found by Pesheva et al., in which
galectin-3 was found to stimulate neural cell adhesion and moreover, neurite outgrowth in developing
cells [50]. This also provides further evidence that the ADSCs are responding favorably to the CK
treatment, expressing neuronal-related proteins known to be functionally and structurally useful.
3.2. Neurogenic Roles of Cytokines
Cytokines are pleotropic proteins that coordinate signaling across varied tissues and cell types
including during neural development [51]. Cytokines display functional roles in a variety of
developmental stages, acting as neurotrophic factors initiating the repair and regeneration of cells [51].
Furthermore, certain groups of cytokines, such as chemokines, regulate the directed growth and
communication between radially migrating neuronal cells which give rise to mature neurons, glial,
astrocytes and oligodendrocytes [51]. Due to their relatively low abundance and the dynamic range
of a proteome, these molecules are extremely difficult to detect by MS and alternative detection
methods, such as the Bioplex cytokine, chemokine, and growth factor assay system, allows the relative
quantitation and comparison of 27 secreted cytokines. Hierarchical group clustering was carried out
to identify the cytokines that responded with similar trends during the differentiation process and
possible roles within the CK treated cells relative to neurogenesis.
The cytokine expression changes in the CK treated ADSCs closely support the proteomic data
displaying a similar broad change in concentrations and the thus cellular phenotype in response to
treatment. The intimate view of the cytokines is vital in understanding their corresponding roles
in neural development and growth. The concentration change of molecules from group 1 (IL-1ra,
IL-2, MIP-1b, RANTES and MIP-1a) was apparent with the out of trend large fluctuation of MIP-1b
and RANTES in the LK treated ADSCs (See supplementary material for detailed grouping). MIP-1b
is a pro-inflammatory protein which displayed a substantial increase at 20 h in LK, indicating a
significant pro-inflammatory affect. Interestingly, the increase in MIP-1b is mirrored by RANTES with
a proceeding concentration increase at the same time point. The secretion of MIP-1b has been noted in a
number of neuronal cells [52]. The developmental organization of neuronal cells and CNS development
have been linked to a synchronous regulation of MIP-1b alongside other chemokines [53]. Studies
Int. J. Mol. Sci. 2019, 20, 523 14 of 19
have shown that MIP-1b knockout mice soon die after birth due to brain formation abnormalities [53].
Thus, the role of MIP-1b in ADSCs has gained some interest especially with a number of co-regulations
at the same time point in other cytokine groups. RANTES, also a pro-inflammatory cytokine, was
found to initiate neuro-protective roles assisting in the survival of stressed hippocampal cell lines in
the presence of a toxin [54]. Interestingly a study conducted into investigating the effect of certain pain
management drugs in patients with HIV found that morphine treatment deregulated and decreased
the expression of RANTES in the neuronal tissue. This progressive effect was implicated in the decrease
in microglial cell migration due to the suppression of the chemotactic cytokine [55]. Furthermore,
another study into the effect of HIV glycoprotein120 on neuronal tissue presented a number of up
regulated secreted pro-inflammatory cytokines including RANTES which offered a neuroprotective
role [56]. These responses all lead to the stimulation of the CX3CL1, CCL4 and CCL5 receptors of the
above cytokines [53] which may also be regulated in the differentiating ADSCs.
Examining beyond group 1 with the consideration of the 20 h time point, a number of similar
variations in trends were identified amongst several cytokines in other groups. The decrease of IL-15 is
a significant find as its expression and regulation, through an indirect neuroprotective mechanism, in
astroglial cells has been found to be linked to RANTES, MIP-1a, MIP-1b and GM-CSF [57]. Interestingly
IL-15, IL-17 and GM-CSF in LK’s group 5 present a massive decrease in concentration per cell from the
5 to 20 h time point. Elevated concentrations of IL-15 in neural stem cell (NSC) cultures have proven to
reduce maturation and neurite out growth in differentiating neurons but not affect proliferation [58].
Furthermore, IL-15-deficient mice exhibited defective JAK/STAT and ERK pathways which are key in
the regulation of differentiation in NSCs. This substantiates the possible role for the decrease of IL-15
in LK treated ADSCs which presented greater morphological differentiation than the AECK treated
cells. The down regulation of IL-17 is also considered a beneficial decrease for cytokines in brain tissue,
since elevated levels are usually present in a number of traumatic brain injuries or infarcts in which a
large proportion of cells are damaged [59].
The cytokine (Bioplex) data complement the proteomic findings that the AECK and LK treatments
of ADSCs initiate the differentiation toward a neural lineage and potentially neurons, evidenced by
the proteomic and microscopic analyses. The results also indicate the ADSCs favor the treatment with
LK over AECK for neuronal-like differentiation within the 24 h treatment time. Notwithstanding
the AECK did produce a slightly higher cell population at the end of the differentiation time and
similar neurogenic-related proteins were identified. The cytokine data also are consistent with a lack
of cytotoxic stress of the cells over the period examined, thus removing cytotoxicity as a cause for the
neuronal-like morphological changes [7].
4. Materials and Methods
4.1. Cell Culture
4.1.1. Human Adipose Derived Stem Cells Harvest and Cell Culture
The procedures of adult ADSCs isolation and expansion were used from Santos et al., 2017 [6]
in accordance with guidelines and regulations under Macquarie University Human Research Ethics
Committee approval (MQ-HREC Ref #: 5201100385, 8 March 2011). All donor participants volunteered
through informed consent for lipoaspirate donation as per ethics guidelines and were de-identified
for research purposes. Generally, ADSCs were maintained in T175 flask (Nunc, ThermoScientific,
Carlsbad, CA, USA) in 15 mL D-MEM Glutmax/F12 (Gibco, Life Technologies, Carlsbad, CA,
USA) with 10% Foetal Bovine Serum (FBS, Gibco, Life Technologies, Carlsbad, CA, USA) and 1%
Antibiotics/Antimycotics (ABAM, Gibco, Life Technologies, Carlsbad, CA, USA) incubated at 37 ◦C
at 5% ADSCs were passaged 3–5 post isolation times by stripping cells with TrypLE Express (12604
Gibco, Life Technologies, Roskilde, Denmark) before being utilized in differentiation experiments.
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4.1.2. Chemical Induction for Differentiation
Sub-confluent ADSCs were washed twice in pre-warmed sterile D-MEM/F12 (Gibco, Life
Technologies, Carlsbad, CA, USA). The cells were then cultured for a further 24 h in a serum-free
pre-induction medium consisting of D-MEM/F12 (Invitrogen), ABAM (Gibco, Life Technologies,
Carlsbad, CA, USA) and 10% of the final concentration of the added Ketamine. The media was then
replaced after 24 h with the neuronal inducing media consisting of D-MEM/F12, ABAM and the final
optimized concentrations of 0.5 mM AECK, or 0.6 mM LK, or 0.3 mM LKEE.
4.1.3. Glioblastoma Cell Culture
The GBC line was cultured in neurobasal media supplemented with B27 and 0.5 mM Glutamine
(Gibco, Life Technologies, Carlsbad, CA, USA). The cells were grown to 90% confluence prior to
passaging or harvesting for proteomics.
4.2. Microscopy
Cell Counts
In vitro cell counts were carried out utilizing a procedure described in Santos et al., 2017 [6] to
determine the approximate colony forming units per square millimeter. The total cell number data was
also utilized in the Bioplex analysis to determine the amount of cytokines secreted per cell. This was
calculated by multiplying the concentration by the total volume of the flask and dividing by the total
cell number at the respective time point.
4.3. Protein Extraction
Harvesting cells for proteomic analysis by LC-MS/MS or iTRAQ and Western blot (see
Supplementary Material) were completed at the desired end time point as per Santos et al., 2017 [6].
4.4. iTRAQ
iTRAQ labelling and mass spectrometry were followed as per [6] with the following modifications;
after cell lysis and protein extraction, there were a total of 4 samples for iTRAQ labelling (1—ADSCs,
2—AECK treated hADSC, 3—LK treated hADSC and 4—Glioblastoma control (GBCs)). AECK and LK
data sets checked for normalized data distribution and volcano plots were generated using DanteR
software [59]. Post hoc interaction network analysis was performed on Cytoscape (version 3.5.1,
Cytoscape Consortium, Seattle, WA, USA) [11].
4.5. Bioplex
Bioplex analysis was performed as per Santos et al., [6] with 500 µL aliquots collected
differentiation timepoints at 0, 0.5, 1, 3, 5, 20 and 24 h Assay was performed with Bioplex human
27-plex (M50-0KCAF0Y Bio-Rad Laboratories, Hercules, CA, USA). Data analysis was completed in
DanteR software (DanteR version 1.0.0.10. R version 2.12.0 The R Foundation for Statistical Computing,
Auckland, New Zealand) [59].
5. Conclusions
This study aimed to investigate the extent of proteomic change in ADSCs treated with two
different CKs compounds LK and AECK for the purpose of a directed neurogenic induction
differentiation. The extent of differentiation was investigated by the changes in the proteome occurring
during the process. The treatments indicated that the ADSCs responded favorably to the neurogenic
induction media by presenting a number of morphological cues previously observed [4,6] and a
higher cell population post induction compared to previous studies with BME [6]. Furthermore,
a variety of proteins were identified by mass spectrometric analyses a number of neurogenic and
Int. J. Mol. Sci. 2019, 20, 523 16 of 19
stress related proteins have been up-regulated, most of which are noted in the literature to have
positive effects for neurogenic differentiation. A number of the statistically significant proteins were
explored, investigating their known function in developing neurons and their associated role within
the treated cells. Complementing the iTRAQ quantitative proteomic data, the Bioplex system allowed
the investigation of a closed cohort of cytokines and interleukins allowing trends to be examined,
allowing a closer look at the smaller and lower copy number proteins that have numerous profound
affects in the immunogenicity and stress response of cells.
Here we have shown that the treatment of ADSCs with the CK compounds, AECK and LK, have
the potential to induce ADSCs toward a neurogenic phenotype, producing similar morphological traits
established in previous studies but with the added benefit of being seemingly non-toxic at the utilized
concentrations as indicated by cell counts. The supporting evidence of the expression of a wide range
of neural-related proteins which have not been previously utilized as neural markers but are known to
play an integral role in the neuronal maturation and development of the CNS, further infers the CK’s
differentiation function. Thus, the novel application of CK’s to produce a neurogenic cell population
within 24 h of induction holds potential for further applications for neuroregeneration and in studies
in the transdifferentiation of ADSCs. Future directions will explore neuronal maturation and neuronal
activity by action potential measurement.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/3/
523/s1.
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hADSCs human adipose derived stem cells
iTRAQ Isobaric tag for relative and absolute quantitation
LK lanthionine ketamine
LKEE lanthionine ketamine ethyl ester
MSC mesenchymal stromal/stem cells
MSMS tandem mass spectrometry
PBS phosphate buffered saline
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